Immunoglobulin heavy chain variable region gene usage and mutational status of the leukemic B cells in Iranian patients with chronic lymphocytic leukemia
Mohammad Hojjat‐Farsangi(Karolinska University Hospital), Hodjatallah Rabbani(Biotechnology Research Center), Seyed Mohsen Razavi(Firoozgar General Hospital), Fazel Shokri(Academic Center for Education, Culture and Research), Ramazan Ali Sharifian(University of Tehran), Mahmood Jeddi‐Tehrani(Academic Center for Education, Culture and Research), Håkan Mellstedt(Karolinska University Hospital)
Cited by 34
Related Papers
Nanoparticles and targeted drug delivery in cancer therapy
|Immunology Letters|2017|507
The significant role of interleukin-6 and its signaling pathway in the immunopathogenesis and treatment of breast cancer
|Biomedicine & Pharmacotherapy|2018|312
CAMPATH-1H monoclonal antibody in therapy for previously treated low-grade non-Hodgkin's lymphomas: a phase II multicenter study. European Study Group of CAMPATH-1H Treatment in Low-Grade Non-Hodgkin's Lymphoma.
|Journal of Clinical Oncology|1998|258
Small-Molecule Inhibitors of the Receptor Tyrosine Kinases: Promising Tools for Targeted Cancer Therapies
|International Journal of Molecular Sciences|2014|202
CDK1 in Breast Cancer: Implications for Theranostic Potential
|Anti-Cancer Agents in Medicinal Chemistry|2020|169